Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00578604
Other study ID # 17035
Secondary ID
Status Completed
Phase N/A
First received December 20, 2007
Last updated March 28, 2017
Start date September 2007
Est. completion date June 2014

Study information

Verified date March 2017
Source Drexel University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this project is to further the development of a non-invasive optically based NIR (Near Infrared) device to enable the quantitative diagnosis, monitoring and treatment optimization of chronic wounds (especially diabetic) in a clinical setting. The end goal of this project is a portable and compact device that would be simple to operate by minimally trained health care personnel. Our animal studies have shown that the early healing of chronic wounds can be characterized by absorption and scattering of light at near infrared wavelengths ranging from 680 nm to 950 nm. If our project is successful we will be providing the clinician the ability to predict if a wound is healing and if a particular treatment is successful in accelerating healing before any changes are observed by wound size contraction or other visible clinical signs. Our hope is that the fNIR optical device will provide conclusive therapeutic treatment information as early as 5 weeks after initial evaluation, before it would be obvious on gross examination of the patient.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Healthy Subject inclusion criteria

- Subjects must be 18-65 years of age

- Subjects must have no history of diabetes

- Subjects must have no history of vascular disease

- Subjects must have no findings of vascular disease on physical examination

- Subjects who are not allergic to Tegaderm

Patient Subject inclusion criteria:

- Subjects must be 18-65 years of age

- Subjects must have documented diabetes mellitus for at least 6 months.

- Subjects must have at least one documented chronic wound for a minimum 8 weeks.

- A chronic wound is defined as any wound that has not healed after 8 weeks and has a minimum surface area of 1cm2. There is no maximum wound size.

- Wound(s) must be secondary to the complications of diabetes, including vascular disease neuropathy, or both.

- Wounds must be on the ankles or feet

- Subjects who are not allergic to Tegaderm

EXCLUSION CRITERIA

- Subject must not be <18 or >65 years of age

- Subjects with major infections, abscesses, or untreated osteomyelitis will be excluded until appropriately treated.

- Subjects will not be excluded based upon the existence of other co-morbidities associated with chronic diabetes, including retinopathy, nephropathy, peripheral neuropathy, or cardiovascular disease except as follows:

- Subjects who have moderate to severe vascular insufficiency (defined as ankle brachial index <0.75 or toe-brachial index <0.5)

- Subjects who are unable to return for weekly follow-up appointments will not be included.

- Pregnant or lactating people will not be invited to participate.

- Subjects who are allergic to Tegaderm

Study Design


Related Conditions & MeSH terms


Intervention

Device:
diffuse near infrared spectroscopy measurements
Measure blood flow to diabetic wounds

Locations

Country Name City State
United States Drexel University College of Medicine Wound Care Center Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Drexel University College of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary diffuse near infrared spectroscopy measurements The end goal of this project is a portable and compact device that would be simple to operate by minimally trained health care personnel and is comparable to SOC doppler. 3 years
See also
  Status Clinical Trial Phase
Completed NCT02652754 - Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers Phase 1
Completed NCT01070433 - A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers Phase 2
Completed NCT00971048 - Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds N/A
Terminated NCT00762138 - The AutoloGel™ Post-Market Surveillance (TAPS) Program N/A
Completed NCT02631512 - Evaluation of Woulgan in Diabetic Foot Ulcer Phase 4
Terminated NCT01816633 - Effectiveness of AutoloGel Therapy in Diabetic Foot Ulcers N/A
Completed NCT02222376 - Effect of Topic Pirfenidone in Diabetic Ulcers Phase 3
Completed NCT01454401 - LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers N/A
Completed NCT01221207 - Instant Total Contact Cast to Heal Diabetic Foot Ulcers N/A
Withdrawn NCT01105884 - Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers N/A
Completed NCT01291160 - Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers Phase 2/Phase 3
Completed NCT00536744 - Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers Phase 3
Terminated NCT00316537 - Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers Phase 1/Phase 2
Completed NCT00013299 - Clinical Trials of Footwear in Patients With Diabetes-Study Arm 2,3 Phase 2
Completed NCT00013286 - A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk Phase 2
Terminated NCT02667327 - A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer Phase 3
Not yet recruiting NCT00916292 - Safety Study of Topical Human FGF-1 for Wound Healing Phase 1
Completed NCT01154374 - A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot) Phase 2
Not yet recruiting NCT02672280 - Safety and Exploratory Efficacy Study of Collagen Membrane With Mesenchymal Stem Cells in the Treatment of Skin Defects Phase 1/Phase 2
Completed NCT02589210 - dHACM Mesh In the Treatment of Diabetic Foot Ulcers N/A